13F-HR: Sarepta Therapeutics Files 13F Holdings Report

Sarepta Therapeutics, Inc. has filed its quarterly 13F holdings report for the period ending March 31, 2026, detailing its investment positions.

Summary

• Sarepta Therapeutics, Inc. has submitted its Form 13F Information Table for the quarter ended March 31, 2026.
• The filing indicates a total of 1 investment holding.
• The total value of the reported holdings is $0.
• Ryan Wong, Executive Vice President and Chief Financial Officer, signed the report on May 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of holdings with no new financial performance data or strategic announcements.

Negatives

• The total reported value of the investment holdings is $0, which may indicate a lack of significant equity investments or a specific reporting strategy.

Future Outlook

No specific forward-looking statements or guidance are provided in this 13F filing, as it is a report of past holdings.

Industry Context

StockSavvy.ai notes that Form 13F filings are standard disclosures for institutional investment managers, providing transparency into their equity holdings. The $0 reported value for Sarepta Therapeutics' holdings in this filing is unusual and warrants further investigation into the company's reporting strategy or specific investment activities during the period.

Key Dates

Keywords

13F, Sarepta Therapeutics, SEC Filing, Investment Holdings, Form 13F-HR, Financial Report